Nikon CeLL Innovation Co., Ltd. (NCLi), a subsidiary of Nikon Corporation, has entered into a strategic licensing agreement with RoosterBio, Inc., a U.S.-based leader in stem cell technology. This partnership aims to establish a comprehensive platform for the development and GCTP/GMP-compliant manufacturing of human mesenchymal stem cells (MSCs) and extracellular vesicle (EV) therapeutics in Japan.
Through this agreement, Japan’s biopharmaceutical sector gains access to an end-to-end solution for MSC and EV therapy development. Drug developers can utilize RoosterBio’s advanced technology platform to accelerate early-stage development with NCLi and seamlessly transition into clinical manufacturing within NCLi’s purpose-built GCTP/GMP facility for cell therapies.
Also Read: Astellas and YASKAWA Form Joint Venture to Advance Automated Cell Therapy Manufacturing
The collaboration enables NCLi to support a full range of capabilities-including cell expansion, harvesting, formulation, and cryopreservation of MSCs using both 2D flask and 3D bioreactor* systems. Additionally, the company can perform downstream processing for EV purification and drug product manufacturing. Technology transfer activities between RoosterBio and NCLi, covering both 2D and 3D bioreactor MSC and EV production at clinically relevant scales, have already been successfully completed.
